Weight-loss drug developer Metsera, backed by ARCH Venture Partners, filed its paperwork for an U.S. IPO on Friday. Strong ...

Tenvie Therapeutics has unveiled with $200 million and the goal of transforming the neurological treatment landscape, nabbing ...

About a year ago, Tenvie President and Chief Scientific Officer Tony Estrada approached Denali CEO Ryan Watts and others in ...

Tenvie Therapeutics is making hay from an R&D shift at Denali Therapeutics, acquiring several of its neuroscience drug ...

After the successful development of mavacamten and the sale of MyoKardia to BMS in 2020, former executives of the biotech are ...

A new company is making its debut with a series A sum that’s sure to make hearts race. | A new company is making its debut ...

Backed by ARCH Venture Partners, F-Prime Capital and Mubadala Capital, the new company will develop a pipeline of ...

“Jami is an industry-leading intellect and advisor to transformational healthcare companies,” said Mark Van Lith, CEO of Guggenheim Securities. “Jami is an important addition to our premier healthcare ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Biotech firm Maze Therapeutics, backed by Third Rock Ventures, revealed a profit for the first nine months of 2024 in its ...

Advancing a deep pipeline of therapeutics focused on treating neurological, cardiometabolic, and ophthalmic diseasesLed by expert R&D ...